Inventor · disambiguated record
Glenn Mark Anderson
Also filed as: ANDERSON GLENN · ANDERSON GLENN M · ANDERSON GLENN MARK
9 granted patents·8 pending applications·110 citations·filing 2001–2022
88Inventor score
Top patents by PatentIndex Score
17 records- 0190US8043616B2sRAGE mimetibody, compositions, methods and usesCENTOCOR INC·Filed 2008·Granted Oct 25, 2011·15 cites·5 claims
- 0289US8951525B2Human tissue factor antibody and uses thereofJANSSEN BIOTECH INC·Filed 2013·Granted Feb 10, 2015·11 cites·17 claims
- 0389US8722044B2Human tissue factor antibody and uses thereofALMAGRO JUAN CARLOS·Filed 2012·Granted May 13, 2014·12 cites·19 claims
- 0488US8999333B2Human tissue factor antibody and uses thereofJANSSEN BIOTECH INC·Filed 2014·Granted Apr 7, 2015·9 cites·15 claims
- 0587US6860235B2Apparatus for creating a pathway in an animal and methods thereforPATHWAY TECHNOLOGIES LLC·Filed 2003·Granted Mar 1, 2005·55 cites·50 claims
- 0686US10844122B2Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereofJANSSEN BIOTECH INC·Filed 2016·Granted Nov 24, 2020·4 cites·8 claims
- 0769US11746157B2PSMA binding agents and uses thereofJANSSEN BIOTECH INC·Filed 2019·Granted Sep 5, 2023·1 cites·81 claims
- 0860US7311925B2Methods and compositions for blocking microbial adherence to eukaryotic cellsZASLOFF MICHAEL A·Filed 2002·Granted Dec 25, 2007·3 cites·16 claims
- 0956US7470434B1Methods and compositions for blocking microbial adherence to eukaryotic cellsZASLOFF MICHAEL A·Filed 2007·Granted Dec 30, 2008·0 cites·8 claims
- 1055US2025277051A1Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereofHANGZHOU UNOGEN BIOTECH LTD·Filed 2022·Application pending·0 cites
- 1154US2025270314A1Anti-cdh17 monoclonal and bispecific antibodies and uses thereofTAVOTEK BIOTECH SUZHOU LTD·Filed 2022·Application pending·0 cites
- 1249US2006084145A1sRAGE mimetibody, compositions, methods and usesANDERSON GLENN M·Filed 2005·Application pending·0 cites
- 1349US2008311034A1Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector FunctionANDERSON GLENN M·Filed 2008·Application pending·0 cites
- 1448US2002072495A1LL-37 is an immunostimulantFiled 2001·Application pending·0 cites
- 1544US2004013679A1LL-37 is an immunostimulantFiled 2003·Application pending·0 cites
- 1637US2017210799A1Anti-ror1, antibodies, ror1 x cd3 bispecific antibodies, and methods of using the sameJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 1731US2003188692A1Apparatus for creating a pathway in an animal and methods thereforFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn Mark Anderson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →